Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Here comes the paper

The dike has given way, as 13 biotech financings closed last week, raising $652 million. The industry has raised $1.5 billion in the first four weeks of 2000. Although the torrent can't be sustained - it otherwise would track out to $19.5 billion for the year - the best-ever $7.6 billion in 1996 and last year's $7.4 billion could be in jeopardy.

Indeed, 11 proposed financings were added to the queue last week, including two more IPOs, promising to add close to $1 billion to the total.

Last week's tally included the industry's second largest follow-on since 1994, a $235.2 million financing for genomics play Gene Logic (GLGC). Biovail (BVF; TSE:BVF) had raised $255 million in a follow-on last October. But both GLGC and BVF will get knocked down a peg if Abgenix (ABGX) sells its proposed 1.8 million-share follow-on at its $163 price prior to filing, which would raise $293.4 million for the antibody company.

The other big transactions last week were two convertible note deals that raised Human Genome (HGSI) and CuraGen (CRGN) $150 million and $125 million, respectively.

Although the BioCentury 100 index fell 11 percent last week, the indicator is still up 26 percent on the year. The looming question is when the new paper will sate investor demand. Judging by the aftermarket performance of recent IPOs and follow-ons, there appears to be enough money - for now - to buy

Read the full 2313 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE